Effect of sertraline on protein binding of warfarin.
The effect of sertraline on the plasma protein binding of warfarin was investigated in a nonblinded randomised placebo-controlled parallel trial in 12 healthy male volunteers. The study participants received single doses of warfarin before administration of sertraline or placebo and again after sertraline or placebo had been administered for 22 days. Treatment with sertraline for 26 days increased the area under the mean prothrombin time vs time curve by 145 sec *h (7.9%), compared with a decrease of 17 sec *h (-1.0%) in the placebo group. Although statistically significant (p = 0.02), this difference was not felt to be clinically meaningful. There appeared to be a slight delay in the normalisation of the prothrombin time in the sertraline-treated group after the second dose of warfarin, which also would not be expected to be clinically significant. After 22 days, a statistically significant (p = 0.02) increase in unbound warfarin was observed in the sertraline group compared with the placebo-treated individuals. Neither the change in prothrombin time nor the change in plasma protein binding were considered to have any clinical relevance; however, good clinical practice dictates that prothrombin time should be monitored in patients treated concurrently with warfarin and sertraline to ensure that the integrity of coagulation response is maintained. The metabolism of warfarin is principally mediated by the cytochrome P450 (CYP) isoenzyme CYP2C9/10. Thus, sertraline appears to have a minimal effect on the CYP2C9/10 isoenzyme.
Apseloff
G
G
Department of Pharmacology, Ohio State University, Columbus, USA.
Wilner
K D
KD
Gerber
N
N
Tremaine
L M
LM
D015057:1-Naphthylamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000328:Adult; D000925:Anticoagulants / Q000097:blood* / Q000378:metabolism; D000928:Antidepressive Agents / Q000494:pharmacology*; D001189:Aryl Hydrocarbon Hydroxylases; D001798:Blood Proteins / Q000378:metabolism; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D006801:Humans; D008297:Male; D006899:Mixed Function Oxygenases / Q000378:metabolism; D011485:Protein Binding; D011517:Prothrombin Time; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D020280:Sertraline; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases / Q000378:metabolism; D014859:Warfarin / Q000097:blood* / Q000378:metabolism
D015057:1-Naphthylamine; D000925:Anticoagulants; D000928:Antidepressive Agents; D001189:Aryl Hydrocarbon Hydroxylases; D001798:Blood Proteins; D065729:Cytochrome P-450 CYP2C9; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D039181:Steroid 16-alpha-Hydroxylase; D013250:Steroid Hydroxylases; D014859:Warfarin; C450260:CYP2C9 protein, human